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Abstract
OBJECTIVE: To investigate the anti-platelet aggre-
gation and antithrombotic effects in rats of iridoid
glycosides extracted from Zhizi (Fructus Gardeniae).
METHODS: The present study evaluated the anti-
thrombotic activity of iridoid glycosides (IGs) in a
rat model of carotid artery thrombosis. The effects
on coagulation, such as thromboplastin time
(APTT), thrombin time (TT) and prothrombin time
(PT), and the effect on collagen-induced platelet
aggregation in vivo were investigated. Rats were in-
tragastrically administered IGs (50, 100 or 200 mg/
kg) twice daily for 3 days.
RESULTS: IGs were shown for the first time to have
an antithrombotic action through the inhibition of
platelet aggregation, with little effect on the coagu-
lation time of peripheral blood. Our results also
showed that IGs may significantly and dose-de-
pendently reduce arterial thrombus load in a mod-
el of carotid artery thrombosis and inhibit colla-
gen-induced platelet aggregation in rats. IGs (100
or 200 mg/kg) had no significant effect on APTT
and PT, but did lengthen TT at a higher dose.
CONCLUSION: These data, together with the previ-
ously reported neuroprotective effects of IGs in rats
with cerebral ischemia, suggest that the antithrom-
botic action of IGs may potentially contribute to
the treatment of cerebral ischemic diseases, includ-
ing cerebral apoplexy.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Studies indicate that antithrombotic therapy should be
adopted for treatment of ischemic disorders, such as ce-
rebral ischemia.1,2 Our recent studies showed that iri-
doid glycosides (IGs), the main active constituent of
Zhizi (Fructus Gardeniae), may exert neuroprotection
against cerebral ischemic damage in several animal
models.3 Two pharmacological approaches are available
for the antithrombotic treatment of ischemic cerebral
apoplexy.4 One approach is to reestablish blood flow to
the ischemic site by dissolving the intraarterial clots us-
ing thrombolytic agents (e.g., tissue plasminogen acti-
vator or urokinase). The other is to inhibit the forma-
tion and spread of intravascular clots using antithrom-
botic agents (e.g., antiplatelet drugs or anticoagulation
agents). Considering the importance of anti-thrombo-
sis in the treatment of ischemic disorders, efforts direct-
ed at searching for novel, better, antithrombotic agents
should be made.
In China, Zhizi (Fructus Gardeniae) is widely used in
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Traditional Chinese Medicine and has been the focus
of recent studies.5,6 Zhizi (Fructus Gardeniae) has been
included in a number of Sino-Japanese herbal prescrip-
tions for the treatment of ischemic diseases for quite a
long time.7,8 IGs, with twomain genipin derivatives (Fig-
ure 1), have been regarded as the main effective constit-
uents of Zhizi (Fructus Gardeniae).9,10 IGs have been
shown to exert neuroprotection in a rat cerebral ischemic
model via a variety of pharmacological properties, includ-
ing antioxidative and anti-apoptotic effects.11-13 In addi-
tion,geniposidewasreportedtosignificantly inhibitplate-
let aggregation at the dose of 7.7 mg/kg.14 Platelet func-
tion is significantly associated with the outcome of isch-
emic disorders, including ischemic cerebral apoplexy,
however, the effects of IGs on platelet function have
not been thoroughly investigated. To further explore
the potential hemodynamic basis of IGs in the treat-
ment of ischemic diseases, the effects of IGs on thrombo-
sis and potentialmodes of actionwere investigated.
MATERIALS ANDMETHODS
Animals
The specific pathogen free male Sprague-Dawley rats,
weighing 280-330 g, were purchased from the Experi-
mental Animal Center, China Three-Gorge University.
Rats were acclimated for 5 days at 25℃±1℃ with a 12 h
light/dark cycle, and allowed free access to food and
water before experiments. All experiments were per-
formed in accordance with the Regulations of Experi-
mental Animal Administration issued in 1988 by the
State Committee of Science and Technology of the Peo-
ple's Republic of China. This study was approved by
the local animal experimentation ethics committee.
IG preparation and administration
IGs were isolated and extracted from the Zhizi (Fructus
Gardeniae) fruit, and purified by D101 resin column
chromatography (Anhui Sanxin Resin Technology Co.,
Ltd., Benbu, China).15 The purity of IGs was examined
by UV spectrophotometry (UV-1700 type ultraviolet
spectrophotometer, Shimadzu, Kyoto, Japan). IGs con-
taining geniposide >30% with purity of iridoid glyco-
sides >80% were used and prepared in 3% (v/v)
Tween-80 (AR, Shanghai Xinran Biotechnology Co.,
Ltd., Shanghai, China). Rats in the control group were
given volume-matched vehicle. Aspirin (Shijiazhuang
Hexie Pharmaceutical Factory, Shijiazhuang, China) or
warfarin sodium (Shanghai Pharmaceutical Co. Ltd.,
Shanghai, China) was used as positive controls in the
appropriate experiments.
In vivo antithrombotic activity
The antithrombotic activity of IGs was determined in a
rat model of carotid artery thrombosis, which was estab-
lished as reported by Kurz with minor modifications.16
Rats were intragastrically administrated with IGs (100
and 200mg/kg), aspirin (20mg/kg), or vehicle twice dai-
ly for 3 days. One hour after administration, rats were
anesthetized using chloral hydrate (320 mg/kg, i.p.).
The left common carotid artery was carefully isolated,
and a plastic sheet was placed under the vessel to sepa-
rate it from the surrounding tissues.The surface of the ca-
rotid artery was covered with a 1 cm×1 cm cotton sheet
saturated with 20 μL of FeCl3 solution (2.16 mol/L) for
15 min. Ninety minutes after the cotton sheet was re-
moved, the injured carotid artery segment (1 cm) was
dissected away and weighed. After drying for 2 h at
70℃ in a dehumidifier, the dry weight of the carotid
artery segment was measured.
In vitro anti-platelet aggregation
Rats received intragastric IGs (50 and 100 mg/kg), as-
pirin (40 mg/kg), or vehicle once daily for 3 days. One
hour after final administration, blood samples (5 mL)
were taken from the carotid artery of chloral hy-
drate-anesthetized rats (320 mg/kg, i.p.) and collected
using 3.8% trisodium citrate as the anticoagulant (9/1,
v/v). Platelet-rich plasma (PRP) was obtained by centri-
fuging the blood sample at 100 rpm for 10 min. Plate-
let-poor plasma (PPP) was obtained by centrifuging at
1200 rpm (10 min, continuously). PRP was adjusted
to 3×108 platelets/mL with PPP. Platelet aggregation in-
duced by the addition of collagen (final concentration,
1 µg/mL) was determined according to Born's meth-
od17 with 2 types of monitors [a whole-blood ag-
gregometer (WBA analyzer; Mebanix, Tokyo, Japan)].
Light transmission of PRP was 0% , and that of PPP
100%. The extent of platelet aggregation was estimated
Figure 1 The structures of geniposide and genipin gentiobioside
A: geniposide; B: genipin gentiobioside.
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quantitatively by measuring the collagen-induced maxi-
mal aggregation.
In vitro anticoagulation activity
Anticoagulation activity was evaluated by measuring
plasma clotting times. Rats received IGs (100 and
200 mg/kg), warfarin (1 mg/kg, p.o.), or vehicle twice
daily for 3 days. One hour after final administration, ci-
trated blood was collected and centrifuged to obtain
PPP as above. Plasma clotting times, activated partial
thromboplastin time (APTT), thrombin time (TT)
and prothrombin time (PT) were determined using an
a STA-R Coagulometer using PT, TT and APTT re-
agent kits (Weifang 3V Bioengineering Group Co.,
Ltd., Weifang, China). PT and TT were measured by
incubation of 50 µL of PPP for 4 min, followed by the
addition of 100 µL of prewarmed PT and TT agent.
APTT was measured by incubation of 50 µL of PPP
with 50 µL of APTT agent for 4 min, followed by the
addition of 50 µL of 25 mM CaCl2.
Statistical analysis
All data were expressed as mean±SD. The SPSS 18.0
software package (IBM SPSS, Chicago, IL, USA) was
used for all statistical calculations. Differences between
the treated and control groups were analyzed using
one-way analysis of variance (ANOVA), followed by
Student's two tailed t-test for comparison between the
two groups. Dunnett's test was used when data in-
volved three or more groups. P<0.05 was considered
significant.
RESULTS
Effect of IGs on carotid artery thrombosis
IGs were found to have an antithrombotic effect in a
rat model of carotid artery thrombosis (Figure 2). Pre-
treatment with IGs for 3 days led to a dose-related re-
duction in thrombus formation. The dry weights of
the thrombus in response to 100 and 200 mg/kg of
IGs were 1.87 and 1.27 mg, respectively. Only 200 mg/
kg of IGs and 20 mg/kg of aspirin could significantly
reduce the weight of thrombus when compared with
controls (P<0.05).
Anti-platelet aggregation of IGs in vitro
We investigated the effect of IGs on maximal platelet
aggregation induced by collagen. As shown in Figure 3,
control rats treated with vehicle had a platelet aggrega-
tion of 69%. Pretreatment with IGs for 3 days dose-de-
pendently reduced collagen-induced platelet aggrega-
tion in vitro. The maximal platelet aggregation was sig-
nificantly lowered in the 100 mg/kg IGs group (13%)
and in the 50 mg/kg IGs group (24% ) as compared
with the controls (P<0.01). Aspirin at a dose of 40 mg/
kg decreased the maximal platelet aggregation to 18%
(P<0.01 vs control group).
Effects of IGs on in vitro coagulation times
The effects of IGs on coagulation times were evaluated
by APTT, TT and PT assays in rats in vitro. As shown
inFigure4, oral administrationof IGs (100or200mg/kg)
for 3 days did not markedly affect PT or APTT, as
compared with controls (P>0.05). Warfarin (1.0 mg/
kg) significantly prolonged PT and APTT when com-
pared with controls and the IG-treated groups (P<0.01).
Interestingly, IGs (200 mg/kg) prolonged TT as com-
a
b
b
Figure 4 Effects of IGs on coagulation parameters in rats (n=
10 rats for each group)
IGs: iridoid glycosides. IGs 100: iridoid glycosides 100 mg/kg;
IGs 200: iridoid glycosides 200 mg/kg. Compared with con-
trol group, aP<0.05, bP<0.01.
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Figure 2 Effect of IGs on thrombus formation in a rat model
of carotid artery thrombosis (n=6 rats for each group)
IGs: iridoid glycosides; Aspirin 20: aspirin 20 mg/kg; IGs 100:
iridoid glycosides 100 mg/kg; IGs200: iridoid glycosides 200
mg/kg. Compared with control group, aP<0.05.
a
a
Figure 3 Effects of IGs on collagen-induced platelet aggrega-
tion (tested by whole-blood aggregometer) in vitro in plas-
ma samples taken from pretreated model rats (n=6 rats for
each group)
IGs: iridoid glycosides; Aspirin 40: aspirin 40 mg/kg; IGs 50: iri-
doid glycosides 50 mg/kg; IGs 100: iridoid glycosides 100
mg/kg. Compared with control group, aP<0.01.
a
a
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pared with controls. These results demonstrate that
IGs at these doses have very little effect on the coagula-
tion system.
DISCUSSION
Antithrombotic therapy is effective in the treatment of
ischemic cerebral apoplexy by improving cerebral
blood flow.2 The present study evaluated the effects of
IGs on arterial-type thrombus formation in a rat mod-
el of carotid artery thrombosis. Oral administration of
IGs at doses of 100 and 200 mg/kg can significantly re-
duce thrombus formation. The antithrombotic action
of IGs at these doses was similar to 40 mg/kg of aspirin.
Arterial thrombus formation is mainly due to platelet
aggregation.18 Platelets play a vital role in both the initi-
ation and growth of thrombi. Inhibition of platelet func-
tion, therefore, is a promising approach for the preven-
tion and control of thrombotic disorders. In the present
study, the effect of IGs on platelet function was assessed
by collagen-induced platelet aggregation. The results
showed that oral administration of IGs (50 and
100 mg/kg) for 3 days may significantly prevent platelet
aggregation induced by collagen. The inhibitory potency
of IGs at these doses was similar to that of 40mg/kg aspi-
rin, suggesting that the antithrombotic activity of IGs
might result from anti-platelet aggregation.
The effects of IGs on coagulation times were evaluated
with APTT, TT and PT assays using rat PPP in vitro. As
reported by Sato,19 after oral administration of IGs (100
or 200 mg/kg) for 3 days, no effect on either APTT or
PT was observed, but warfarin (1 mg/kg) significantly
prolonged APTT and PT, indicating that the antithrom-
botic activity of IGs may not be associated with the ex-
trinsic or intrinsic coagulation system. Nevertheless,
IGs could markedly inhibit TT, while warfarin had no
effect. It can be speculated that IGs may directly inter-
act with thrombin, while warfarin only influence the
pre-coagulation process but not thrombin itself.
In most cases, Zhizi (Fructus Gardeniae) is used for
cooling the blood and improving blood circulation in
the treatment of ischemic diseases. Results from the
present study provide new evidence for IGs, extracted
from Zhizi (Fructus Gardeniae), possessing an anti-
thrombotic effect. IGs may be a novel potent anti-
thrombotic agent, but the mode of action is likely asso-
ciated with anti-platelet aggregation rather than antico-
agulation. This action may contribute to neuroprotec-
tion against ischemic cerebral damage.
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